Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Neladalkib Proves Effective in TKI-Pretreated, Advanced ALK+ NSCLC

November 17th 2025

Neladalkib elicited responses and was active in the CNS in TKI-pretreated patients with advanced ALK-positive NSCLC, including lorlatinib-naive patients.

Zanidatamab Plus Chemo ± Tislelizumab Impresses in HER2+ Gastroesophageal Adenocarcinoma

November 17th 2025

Zanidatamab-based regimens improved PFS and OS vs chemotherapy in HER2+ gastroesophageal adenocarcinoma, positioning the agent as a potential new standard.

Five Under 5: Top Oncology Videos for the Week of 11/9

November 16th 2025

The top 5 OncLive TV videos of the week cover insights in breast cancer, uveal melanoma, prostate cancer, and multiple myeloma.

Advances With Checkpoint Inhibitors, T-Cell Engagers, and ADCs Converge to Reshape the SCLC Treatment Paradigm

November 16th 2025

Charles M. Rudin, MD, PhD, discussed evolving standards of care and emerging therapeutics of interest in the SCLC treatment paradigm.

The OncFive: Top Oncology Articles for the Week of 11/9

November 15th 2025

The FDA has approved ziftomenib for NPM1-positive acute myeloid leukemia, has accepted a NDA for 177Lu-edotreotide for GEP-NETs, and more.

AMT-253 Demonstrates Early Efficacy and Manageable Safety in Melanoma

November 15th 2025

AMT-253 delivered durable responses in patients with melanoma with manageable toxicity, supporting continued development.

Adjuvant Satri-Cel Displays Preliminary Activity in Pancreatic Ductal Adenocarcinoma

November 14th 2025

Satri-cel displayed preliminary efficacy when used as adjuvant treatment in patients with pancreatic ductal adenocarcinoma.

Five Under 5: Top Oncology Videos for the Week of 11/2

November 9th 2025

The top 5 OncLive TV videos of the week cover insights in breast cancer and ovarian cancer.

Frontline STK-012 Plus Pembrolizumab and Chemo Shows Early Promise in PD-L1–Negative NSCLC

November 9th 2025

STK-012 plus pembrolizumab and chemotherapy showed early efficacy and manageable safety in PD-L1–negative NSCLC.

The OncFive: Top Oncology Articles for the Week of 11/2

November 8th 2025

The FDA clears subcutaneous daratumumab in smoldering myeloma, adds REMS guidelines for pexidartinib in TGCT, and more.

OncLive’s October EMA Regulatory Recap: Key EU Approvals in Oncology

November 3rd 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in October 2025.

Five Under 5: Top Oncology Videos for the Week of 10/26

November 2nd 2025

The top 5 OncLive TV videos of the week cover insights in myeloproliferative neoplasms, lung cancer, ovarian cancer, and prostate cancer.

The OncFive: Top Oncology Articles for the Week of 10/26

November 1st 2025

Belzutifan-based combinations meet end points in RCC, imaging agent under review for SSTR-positive neuroendocrine tumors, and more.

Federal Funding Cuts Hit Cancer Research Despite Public Support

October 31st 2025

Primo Nery Lara, Jr., MD, and Suneel Kamath, MD, discuss the effects of federal cuts to cancer research despite public support for funding this research.

OncLive’s October Roundup of Key FDA Approvals in Oncology: 4 Decisions to Know

October 31st 2025

Here is your guide to all therapeutic options that were approved by the FDA in October 2025 spanning tumor types.

The Future of Pathology with AI: Future Directions and Clinical Implementation

October 30th 2025

Experts envision AI rapidly analyzing digitized pathology slides to assist diagnosis, highlight uncertainties, assess tumor heterogeneity, and more.

The Future of Pathology With AI: Predicting Prognosis and Personalized Treatment

October 30th 2025

The Future of Pathology With AI: Molecular Subtyping and Genetic Testing

October 30th 2025

Experts discuss how AI can rapidly predict molecular subtypes from H&E slides with 87% accuracy, enhancing but not replacing genomic testing.

The Future of Pathology With AI: Practical Applications

October 30th 2025

Experts discuss how AI can diagnose cancer from standard H&E slides while accounting for slide quality differences to support broader clinical use.

The Future of Pathology With AI: Setting the Stage

October 30th 2025

Experts provide an overview of AI's integration into modern pathology and the development of foundation models for cancer diagnosis.